Welcome!

News Feed Item

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

https://www.reportbuyer.com/product/2225949/Licensing-Terms-and-Agreements-in-Pharma-Biotech-and-Diagnostics.html

The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter licensing deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part.

Chapter 4 provides a review of the leading licensing deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of licensing financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

Chapters 6 and 7 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of licensing deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing dealmaking, enabling thorough learning, education and due diligence prior and during the licensing dealmaking process.

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in licensing dealmaking

2.1. Introduction
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2009
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals

Chapter 3 – Overview of licensing deal structure

3.1. Introduction
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1: Ignyta – Nerviano Medical Sciences – November 2013
3.3.1.b. Case study 2: Sanofi - Pozen – September 2013
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure – January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals – September 2013
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5: Forest Laboratories - Trevena – May 2013
3.4.2.b. Case study 6: Abbvie – Receptos – March 2013

Chapter 4 – Leading licensing deals

4.1. Introduction
4.2. Top licensing deals by value
4.3. Most active licensing dealmakers
4.3.1 Most active licensing dealmakers by therapy
4.3.2. Most active licensing dealmaker by stage of development
4.4. Bigpharma licensing deal activity
4.4. Bigbiotech licensing deal activity

Chapter 5 – Licensing deal term benchmarks

5.1. Introduction
5.2.1. Licensing headline values
5.2.2. Licensing upfront payments
5.2.3. Licensing milestone payments
5.2.4. Licensing royalty rates

Chapter 6 – Bigpharma licensing deals

6.1. Introduction
6.2. How to use licensing deals
6.3. Company licensing agreement listings

Chapter 7 – Bigbiotech licensing deals

7.1. Introduction
7.2. How to use licensing deals
7.3. Company licensing agreement listings

Chapter 8 – Licensing contract directory 2009-2014

8.1. Introduction
8.2. Company A-Z

Appendices

Appendix 1 – Licensing dealmaking - by financial disclosure
Appendix 2 – Licensing dealmaking - by companies A-Z
Appendix 3 – Licensing dealmaking - by stage of development
Appendix 4 – Licensing dealmaking - by therapeutic target
Appendix 5 – Licensing dealmaking - by technology type

Table of figures

Figure 1: Definition of licensing
Figure 2: Situations where licensing can prove useful
Figure 3: Key attributes of a licensing deal
Figure 4: Trends in licensing deal announcements, 2009-2014
Figure 5: Licensing deals signed at each phase of development, 2009-2014
Figure 6: Licensing deals by therapy area, 2009-2014
Figure 7: Licensing agreements – what should a contract include?
Figure 8: Components of the licensing deal structure
Figure 9: Top licensing deals by value since 2009 exceeding $1bn
Figure 10: Most active licensing dealmakers 2009-2014
Figure 11: Most active licensing dealmakers 2009-2014 by therapy area
Figure 12: Most active licensing dealmakers 2009-2014 – by stage of development
Figure 13: Bigpharma – top 50 – licensing deals 2009 to 2014
Figure 14: Bigpharma licensing deal frequency - 2009 to 2014
Figure 15: Bigbiotech – top 50 – licensing deals 2009 to 2014
Figure 16: Bigbiotech licensing deal frequency - 2009 to 2014
Figure 17: Licensing deal headline value distribution, US$million – discovery stage
Figure 18: Licensing deal headline value distribution, US$million – preclinical stage
Figure 19: Licensing deal headline value distribution, US$million – phase I stage
Figure 20: Licensing deal headline value distribution, US$million – phase II stage
Figure 21: Licensing deal headline value distribution, US$million – phase III stage
Figure 22: Licensing deal headline value distribution, US$million – regulatory stage
Figure 23: Licensing deal headline value distribution, US$million – marketed stage
Figure 24: Summary median licensing headline value by stage of development, 2009-2014
Figure 25: Licensing deal upfront payment distribution, US$million – discovery stage
Figure 26: Licensing deal upfront payment distribution, US$million – preclinical stage
Figure 27: Licensing deal upfront payment distribution, US$million – phase I stage
Figure 28: Licensing deal upfront payment distribution, US$million – phase II stage
Figure 29: Licensing deal upfront payment distribution, US$million – phase III stage
Figure 30: Licensing deal upfront payment distribution, US$million – regulatory stage
Figure 31: Licensing deal upfront payment distribution, US$million – marketed stage
Figure 32: Summary median licensing upfront payments by stage of development, 2009-2014
Figure 33: Licensing deal milestone distribution, US$million – discovery stage
Figure 34: Licensing deal milestone distribution, US$million – preclinical stage
Figure 35: Licensing deal milestone distribution, US$million – phase I stage
Figure 36: Licensing deal milestone distribution, US$million – phase II stage
Figure 37: Licensing deal milestone distribution, US$million – phase III stage
Figure 38: Licensing deal milestone distribution, US$million – regulatory stage
Figure 39: Licensing deal milestone distribution, US$million – marketed stage
Figure 40: Licensing deals with royalty rates, %
Figure 41: Licensing deal royalty rate distribution, US$million – discovery stage
Figure 42: Licensing deal royalty rate distribution, US$million – preclinical stage
Figure 43: Licensing deal royalty rate distribution, US$million – phase I stage
Figure 44: Licensing deal royalty rate distribution, US$million – phase II stage
Figure 45: Licensing deal royalty rate distribution, US$million – phase III stage
Figure 46: Licensing deal royalty rate distribution, US$million – regulatory stage
Figure 47: Licensing deal royalty rate distribution, US$million – marketed stage
Figure 48: Summary median licensing royalty rate by stage of development, 2009-2014
Figure 49: Online partnering resources
Figure 50: Deal type definitions

Read the full report:
Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

https://www.reportbuyer.com/product/2225949/Licensing-Terms-and-Agreements-in-Pharma-Biotech-and-Diagnostics.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In past @ThingsExpo presentations, Joseph di Paolantonio has explored how various Internet of Things (IoT) and data management and analytics (DMA) solution spaces will come together as sensor analytics ecosystems. This year, in his session at @ThingsExpo, Joseph di Paolantonio from DataArchon, added the numerous Transportation areas, from autonomous vehicles to “Uber for containers.” While IoT data in any one area of Transportation will have a huge impact in that area, combining sensor analytic...
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
Charles Araujo is an industry analyst, internationally recognized authority on the Digital Enterprise and author of The Quantum Age of IT: Why Everything You Know About IT is About to Change. As Principal Analyst with Intellyx, he writes, speaks and advises organizations on how to navigate through this time of disruption. He is also the founder of The Institute for Digital Transformation and a sought after keynote speaker. He has been a regular contributor to both InformationWeek and CIO Insight...
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.
It is of utmost importance for the future success of WebRTC to ensure that interoperability is operational between web browsers and any WebRTC-compliant client. To be guaranteed as operational and effective, interoperability must be tested extensively by establishing WebRTC data and media connections between different web browsers running on different devices and operating systems. In his session at WebRTC Summit at @ThingsExpo, Dr. Alex Gouaillard, CEO and Founder of CoSMo Software, presented ...
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world.
At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
In a world where the internet rules all, where 94% of business buyers conduct online research, and where e-commerce sales are poised to fall between $427 billion and $443 billion by the end of this year, we think it's safe to say that your website is a vital part of your business strategy. Whether you're a B2B company, a local business, or an e-commerce site, digital presence is key to maintain in your drive towards success. Digital Performance will take priority in 2018 for the following reason...
One of the biggest challenges with adopting a DevOps mentality is: new applications are easily adapted to cloud-native, microservice-based, or containerized architectures - they can be built for them - but old applications need complex refactoring. On the other hand, these new technologies can require relearning or adapting new, oftentimes more complex, methodologies and tools to be ready for production. In his general session at @DevOpsSummit at 20th Cloud Expo, Chris Brown, Solutions Marketi...
I think DevOps is now a rambunctious teenager - it's starting to get a mind of its own, wanting to get its own things but it still needs some adult supervision," explained Thomas Hooker, VP of marketing at CollabNet, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
The “Digital Era” is forcing us to engage with new methods to build, operate and maintain applications. This transformation also implies an evolution to more and more intelligent applications to better engage with the customers, while creating significant market differentiators. In both cases, the cloud has become a key enabler to embrace this digital revolution. So, moving to the cloud is no longer the question; the new questions are HOW and WHEN. To make this equation even more complex, most ...
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time t...
CloudEXPO New York 2018, colocated with DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.